PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
PET tracers for somatostatin receptor imaging of neuroendocrine tumors : current status and review of the literature. / Johnbeck, Camilla Bardram; Knigge, Ulrich; Kjær, Andreas.
I: Future Oncology, Bind 10, Nr. 14, 11.2014, s. 2259-2277.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - PET tracers for somatostatin receptor imaging of neuroendocrine tumors
T2 - current status and review of the literature
AU - Johnbeck, Camilla Bardram
AU - Knigge, Ulrich
AU - Kjær, Andreas
PY - 2014/11
Y1 - 2014/11
N2 - Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.
AB - Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.
U2 - 10.2217/fon.14.139
DO - 10.2217/fon.14.139
M3 - Review
C2 - 25471038
VL - 10
SP - 2259
EP - 2277
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 14
ER -
ID: 137324436